Literatur
- 1
Brieger P.
Bipolare affektive Störungen. Teil I: Diagnostik, Epidemiologie und Verlauf.
Fortschr Neurol Psychiatr.
2007;
75
673-684
- 2
Craddock N, Forty L.
Genetics of affective (mood) disorders.
Eur J Hum Genet.
2006;
14
660-668
- 3
Kato T.
Molecular genetics of bipolar disorder and depression.
Psychiatry and Clinical Neurosciences.
2007;
61
3-19
- 4
Schulze T G, Hedeker D, Zandi P, Rietschel M, McMahon F J.
What Is Familial About Familial Bipolar Disorder? Resemblance Among Relatives Across
a Broad Spectrum of Phenotypic Characteristics.
Archives of General Psychiatry.
2006;
63
1368-1376
- 5
Lerer B, Segman R H.
Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects
for clinical implementation.
Dialogues Clin Neurosci.
2006;
8
85-94
- 6
Alda M, Grof P, Rouleau G A, Turecki G, Young L T.
Investigating responders to lithium prophylaxis as a strategy for mapping susceptibility
genes for bipolar disorder.
Prog Neuropsychopharmacol Biol Psychiatry.
2005;
29
1038-1045
- 7
Einat H, Yuan P, Szabo S T, Dogra S, Manji H K.
Protein kinase C inhibition by tamoxifen antagonizes manic-like behavior in rats:
implications for the development of novel therapeutics for bipolar disorder.
Neuropsychobiology.
2007;
55
123-131
- 8
Zobel A, Maier W.
Endophänotypen - ein neues Konzept zur biologischen Charakterisierung psychischer
Störungen.
Der Nervenarzt.
2004;
75
205-214
- 9
Akiskal H S, Brieger P, Mundt C, Angst J, Marneros A.
Temperament und affektive Störungen. Die TEMPS-A-Skala als Konvergenz europäischer
und US-amerikanischer Konzepte.
Nervenarzt.
2002;
73
262-271
- 10
Chiaroni P, Hantouche E G, Gouvernet J, Azorin J M, Akiskal H S.
The cyclothymic temperament in healthy controls and familially at risk individuals
for mood disorder: endophenotype for genetic studies?.
J Affect Disord.
2005;
85
135-145
- 11
Hallam K T, Olver J S, Chambers V. et al .
The heritability of melatonin secretion and sensitivity to bright nocturnal light
in twins.
Psychoneuroendocrinology.
2006;
31
867-875
- 12
Hajek T, Carrey N, Alda M.
Neuroanatomical abnormalities as risk factors for bipolar disorder.
Bipolar Disord.
2005;
7
393-403
- 13
Drevets W C.
Neuroimaging studies of mood disorders.
Biological Psychiatry.
2000;
48
813-829
- 14
Scherk H, Reith W, Falkai P.
Hirnstrukturelle Veränderungen bei bipolaren affektiven Störungen.
Nervenarzt.
2004;
75
861-872
- 15
Savitz J, Solms M, Ramesar R.
Neuropsychological dysfunction in bipolar affective disorder: a critical opinion.
Bipolar Disorders.
2005;
7
216-235
- 16
Strakowski S M, Delbello M P, Adler C M.
The functional neuroanatomy of bipolar disorder: a review of neuroimaging findings.
Mol Psychiatry.
2005;
10
105-116
- 17
Basso M R, Lowery N, Neel J, Purdie R, Bornstein R A.
Neuropsychological impairment among manic, depressed, and mixed-episode inpatients
with bipolar disorder.
Neuropsychology.
2002;
16
84-91
- 18
Olley A, Malhi G S, Batchelor J. et al .
Executive functioning and theory of mind in euthymic bipolar disorder.
Bipolar Disorders.
2005;
7
43-52
- 19
Martinez-Aran A, Vieta E, Colom F. et al .
Neuropsychological performance in depressed and euthymic bipolar patients.
Neuropsychobiology.
2002;
46 Suppl 1
16-21
- 20
Clark L, Iversen S D, Goodwin G M.
A neuropsychological investigation of prefrontal cortex involvement in acute mania.
American Journal of Psychiatry.
2001;
158
1605-1611
- 21
Murphy F C, Rubinsztein J S, Michael A. et al .
Decision-making cognition in mania and depression.
Psychol Med.
2001;
31
679-693
- 22
Malhi G S, Ivanovski B, Hadzi-Pavlovic D. et al .
Neuropsychological deficits and functional impairment in bipolar depression, hypomania
and euthymia.
Bipolar Disord.
2007;
9
114-125
- 23
Martinez-Aran A, Vieta E, Reinares M. et al .
Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar
disorder.
American Journal of Psychiatry.
2004;
161
262-270
- 24
Nehra R, Chakrabarti S, Pradhan B K, Khehra N.
Comparison of cognitive functions between first- and multi-episode bipolar affective
disorders.
J Affect Disord.
2006;
93
185-192
- 25
Robinson L J, Ferrier I N.
Evolution of cognitive impairment in bipolar disorder: a systematic review of cross-sectional
evidence.
Bipolar Disord.
2006;
8
103-116
- 26
Dittmann S, Seemuller F, Schwarz M J. et al .
Association of cognitive deficits with elevated homocysteine levels in euthymic bipolar
patients and its impact on psychosocial functioning: preliminary results.
Bipolar Disord.
2007;
9
63-70
- 27
Altshuler L L, Ventura J, Gorp W van G. et al .
Neurocognitive function in clinically stable men with bipolar I disorder or schizophrenia
and normal control subjects.
Biological Psychiatry.
2004;
56
560-569
- 28
Torrent C, Martinez-Aran A, Amann B. et al .
Cognitive impairment in schizoaffective disorder: a comparison with non-psychotic
bipolar and healthy subjects.
Acta Psychiatrica Scandinavica.
2007;
116
453-460
- 29
Borkowska A, Rybakowski J K.
Neuropsychological frontal lobe tests indicate that bipolar depressed patients are
more impaired than unipolar.
Bipolar Disorders.
2001;
3
88-94
- 30
Martinez-Aran A, Vieta E, Torrent C. et al .
Functional outcome in bipolar disorder: the role of clinical and cognitive factors.
Bipolar Disord.
2007;
9
103-113
- 31
Dickerson F B, Boronow J J, Stallings C R. et al .
Association between cognitive functioning and employment status of persons with bipolar
disorder.
Psychiatr Serv.
2004;
55
54-58
- 32
Laes J R, Sponheim S R.
Does cognition predict community function only in schizophrenia?: A study of schizophrenia
patients, bipolar affective disorder patients, and community control subjects.
Schizophr Res.
2006;
84
121-131
- 33
Tohen M, Zarate Jr C A, Hennen J. et al .
The McLean-Harvard First-Episode Mania Study: Prediction of Recovery and First Recurrence.
Am J Psychiatry.
2003;
160
2099-2107
- 34
Brieger P, Rottig S, Rottig D, Marneros A, Priebe S.
Dimensions underlying outcome criteria in bipolar I disorder.
Journal of Affective Disorders.
2007;
99
1-7
- 35
Tohen M, Bowden C L, Calabrese J R. et al .
Influence of sub-syndromal symptoms after remission from manic or mixed episodes.
Br J Psychiatry.
2006;
189
515-519
- 36
Fountoulakis K N, Vieta E, Sanchez-Moreno J. et al .
Treatment guidelines for bipolar disorder: a critical review.
J Affect Disord.
2005;
86
1-10
- 37
American Psychiatric Association .
Practice guideline for the treatment of patients with bipolar disorder (revision).
American Journal of Psychiatry.
2002;
159
1-50
- 38
Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines
Team for Bipolar Disorder .
Australian and New Zealand clinical practice guidelines for the treatment of bipolar
disorder.
Aust N Z J Psychiatry.
2004;
38
280-305
- 39
Yatham L N, Kennedy S H, O'Donovan C. et al .
Canadian Network for Mood and Anxiety Treatments (CANMAT) guidelines for the management
of patients with bipolar disorder: update 2007.
Bipolar Disord.
2006;
8
721-739
- 40 National Institute for Health and Clinical Excellence .NICE clinical guideline
38: Bipolar disorder: the management of bipolar disorder in adults, children and adolescents,
in primary and secondary care. London: National Institute for Health and Clinical
Excellence 2006
- 41
Goodwin F K.
The biology of recurrence: new directions for the pharmacologic bridge.
J Clin Psychiatry.
1989;
50 Suppl
40-44; discussion 45 - 47
- 42
Findling R L, Frazier T W, Youngstrom E A. et al .
Double-blind, placebo-controlled trial of divalproex monotherapy in the treatment
of symptomatic youth at high risk for developing bipolar disorder.
J Clin Psychiatry.
2007;
68
781-788
- 43
Judd L L, Akiskal H S, Schettler P J. et al .
Psychosocial disability in the course of bipolar I and II disorders: a prospective,
comparative, longitudinal study.
Arch Gen Psychiatry.
2005;
62
1322-1330
- 44
Gijsman H J, Geddes J R, Rendell J M, Nolen W A, Goodwin G M.
Antidepressants for Bipolar Depression: A Systematic Review of Randomized, Controlled
Trials.
Am J Psychiatry.
2004;
161
1537-1547
- 45
Ketter T A, Calabrese J R.
Stabilization of mood from below versus above baseline in bipolar disorder: a new
nomenclature.
J Clin Psychiatry.
2002;
63
146-151
- 46
Keck Jr P E, Calabrese J R, McQuade R D. et al .
A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently
manic patients with bipolar I disorder.
J Clin Psychiatry.
2006;
67
626-637
- 47
Keck Jr P E, Calabrese J R, McIntyre R S. et al .
Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week,
double-blind study versus placebo.
J Clin Psychiatry.
2007;
68
1480-1491
- 48
Krüger S.
Olanzapin in der Behandlung bipolarer affektiver Erkrankungen.
Psychiatr Prax.
2006;
33 Suppl 1
S18-26
- 49
Geddes J R, Burgess S, Hawton K, Jamison K, Goodwin G M.
Long-Term Lithium Therapy for Bipolar Disorder: Systematic Review and Meta-Analysis
of Randomized Controlled Trials.
Am J Psychiatry.
2004;
161
217-222
- 50
Goodwin G M, Bowden C L, Calabrese J R. et al .
A pooled analysis of 2 placebo-controlled 18-month trials of lamotrigine and lithium
maintenance in bipolar I disorder.
J Clin Psychiatry.
2004;
65
432-441
- 51
Ghaemi S N, Gilmer W S, Goldberg J F. et al .
Divalproex in the treatment of acute bipolar depression: a preliminary double-blind,
randomized, placebo-controlled pilot study.
J Clin Psychiatry.
2007;
68
1840-1844
- 52
Bowden C L, Calabrese J R, McElroy S L. et al .
A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment
of outpatients with bipolar I disorder. Divalproex Maintenance Study Group.
Arch Gen Psychiatry.
2000;
57
481-489
- 53
Gyulai L, Bowden C L, McElroy S L. et al .
Maintenance efficacy of divalproex in the prevention of bipolar depression.
Neuropsychopharmacology.
2003;
28
1374-1382
- 54
Dando T M, Keating G M.
Quetiapine: a review of its use in acute mania and depression associated with bipolar
disorder.
Drugs.
2005;
65
2533-2551
- 55 Severus W E, Kleindienst N, Seemuller F. et al .What is the optimal serum lithium
level in the long-term treatment of bipolar disorder? A review. Bipolar Disord im
Druck
- 56
Zarate Jr C A, Tohen M.
Double-blind comparison of the continued use of antipsychotic treatment versus its
discontinuation in remitted manic patients.
Am J Psychiatry.
2004;
161
169-171
- 57
Okuma T, Inanaga K, Otsuki S. et al .
A preliminary double-blind study on the efficacy of carbamazepine in prophylaxis of
manic-depressive illness.
Psychopharmacology (Berl).
1981;
73
95-96
- 58
Greil W, Ludwig-Mayerhofer W, Erazo N. et al .
Lithium versus carbamazepine in the maintenance treatment of bipolar disorders - a
randomised study.
J Affect Disord.
1997;
43
151-161
- 59
Calabrese J R, Keck Jr P E, Macfadden W. et al .
A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment
of bipolar I or II depression.
Am J Psychiatry.
2005;
162
1351-1360
- 60
Tohen M, Vieta E, Calabrese J. et al .
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar
I depression.
Arch Gen Psychiatry.
2003;
60
1079-1088
- 61
Sachs G S, Nierenberg A A, Calabrese J R. et al .
Effectiveness of adjunctive antidepressant treatment for bipolar depression.
N Engl J Med.
2007;
356
1711-1722
- 62
Calabrese J R, Bowden C L, Sachs G S. et al .
A double-blind placebo-controlled study of lamotrigine monotherapy in outpatients
with bipolar I depression. Lamictal 602 Study Group.
J Clin Psychiatry.
1999;
60
79-88
- 63
Brown E B, McElroy S L, Keck Jr P E. et al .
A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus
lamotrigine in the treatment of bipolar I depression.
J Clin Psychiatry.
2006;
67
1025-1033
- 64
Vieta E, Calabrese J R, Goikolea J M, Raines S, Macfadden W.
Quetiapine monotherapy in the treatment of patients with bipolar I or II depression
and a rapid-cycling disease course: a randomized, double-blind, placebo-controlled
study.
Bipolar Disord.
2007;
9
413-425
- 65
Zarate Jr C A, Payne J L, Singh J. et al .
Pramipexole for bipolar II depression: a placebo-controlled proof of concept study.
Biol Psychiatry.
2004;
56
54-60
- 66
Goldberg J F, Burdick K E, Endick C J.
Preliminary randomized, double-blind, placebo-controlled trial of pramipexole added
to mood stabilizers for treatment-resistant bipolar depression.
Am J Psychiatry.
2004;
161
564-566
- 67
Frangou S, Lewis M, McCrone P.
Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind
placebo-controlled study.
Br J Psychiatry.
2006;
188
46-50
- 68
Frye M A, Grunze H, Suppes T. et al .
A placebo-controlled evaluation of adjunctive modafinil in the treatment of bipolar
depression.
Am J Psychiatry.
2007;
164
1242-1249
- 69
Bschor T, Lewitzka U, Sasse J. et al .
Lithium augmentation in treatment-resistant depression: clinical evidence, serotonergic
and endocrine mechanisms.
Pharmacopsychiatry.
2003;
36 Suppl 3
S230-234
- 70
Nolen W A, Kupka R W, Hellemann G. et al .
Tranylcypromine vs. lamotrigine in the treatment of refractory bipolar depression:
a failed but clinically useful study.
Acta Psychiatr Scand.
2007;
115
360-365
- 71
Gajwani P, Kemp D E, Muzina D J. et al .
Acute treatment of mania: an update on new medications.
Curr Psychiatry Rep.
2006;
8
504-509
- 72
Scherk H, Pajonk F G, Leucht S.
Second-generation antipsychotic agents in the treatment of acute mania: a systematic
review and meta-analysis of randomized controlled trials.
Arch Gen Psychiatry.
2007;
64
442-455
- 73
Licht R W.
Limitations in randomised controlled trials evaluating drug effects in mania.
Eur Arch Psychiatry Clin Neurosci.
2001;
251 Suppl 2
II66-71
- 74
Colom F, Vieta E, Tacchi M J, Sanchez-Moreno J, Scott J.
Identifying and improving non-adherence in bipolar disorders.
Bipolar Disord.
2005;
7 Suppl 5
24-31
- 75 Meyer T D, Hautzinger M. Psychoedukation und Psychotherapie. In: DGBS (ed). Weißbuch
Bipolare Störungen in Deutschland Stand des Wissens - Defizite - Was ist zu tun? 2.
überarbeitete Auflage ed. Hamburg: ConferencePoint Verlag 2006: 325-298
- 76
Scott J, Colom F, Vieta E.
A meta-analysis of relapse rates with adjunctive psychological therapies compared
to usual psychiatric treatment for bipolar disorders.
Int J Neuropsychopharmacol.
2007;
10
123-129
- 77
Colom F, Vieta E, Martinez-Aran A. et al .
A randomized trial on the efficacy of group psychoeducation in the prophylaxis of
recurrences in bipolar patients whose disease is in remission.
Arch Gen Psychiatry.
2003;
60
402-407
- 78 Meyer T, Hautzinger M. Manisch-depressive Störungen. Weinheim: Beltz PVU 2004
- 79 Schaub A, Bernhard B, Gauck L. Kognitiv-psychoedukative Therapie bei bipolaren
Erkrankungen. Ein Therapiemanual. Göttingen: Hogrefe 2004
- 80 Wagner P, Bräunig P. Psychoedukation bei bipolaren Störungen. Ein Therapiemanual
für Gruppen. Stuttgart: Schattauer 2006
- 81
Scott J, Paykel E, Morriss R. et al .
Cognitive-behavioural therapy for severe and recurrent bipolar disorders: Randomised
controlled trial.
Br J Psychiatry.
2006;
188
313-320
- 82
Miklowitz D J, Otto M W, Frank E. et al .
Psychosocial Treatments for Bipolar Depression: A 1-Year Randomized Trial From the
Systematic Treatment Enhancement Program.
Arch Gen Psychiatry.
2007;
64
419-426
- 83
Brieger P, Becker T.
Spezialisierung in der Gemeindepsychiatrie?.
Die Psychiatrie.
2007;
4
216-220
- 84
Kunze H.
Personenzentrierter Ansatz in der psychiatrischen Versorgung in Deutschland.
Psycho.
1999;
25
728-735
Prof. Dr. Peter Brieger
Bezirkskrankenhaus Kempten
Freudental 1
87435 Kempten
Email: peter.brieger@extern.uni-ulm.de
